Results 61 to 70 of about 993 (163)
Rezafungin Prophylactic Efficacy in a Mouse Model of Pneumocystis Pneumonia [PDF]
Biology of Blood and Marrow Transplantation, 2019 Background The risk of Pneumocystis pneumonia often warrants antifungal prophylaxis for bone marrow and solid organ transplantation patients. However, complications such as myelosuppression, nephrotoxicity, and intolerance with the existing standard, TMP/SMX, may hinder or interrupt prophylaxis. Rezafungin (RZF) is a novel echinocandin in development
Melanie Cushion, Alan Ashbaugh
openaire +1 more source
Novel antifungal agents in clinical trials [version 2; peer review: 2 approved]
F1000Research, 2022 Invasive fungal diseases due to resistant yeasts and molds are an important and increasing public health threat, likely due to a growing population of immunosuppressed hosts, increases in antifungal resistance, and improvements in laboratory diagnostics.
Samantha E. Jacobs +2 more
doaj +1 more source
Journal of Fungi, 2022 The isolation of a pan-echinocandin-resistant Candida parapsilosis strain (anidulafungin, caspofungin, micafungin and rezafungin EUCAST MICs > 8 mg/L) from urine of a patient following prolonged exposure to echinocandins (38 days of micafungin followed ...
Maria Siopi +12 more
doaj +1 more source
, 2021 Kutatómunkánk alapján kiderült, hogy a Candida auris dél-afrikai kládjának 2 törzse (2-es és 204-es) érzékeny az echinocandinokra. Az in vivo terápia sikeresen zárult mind a két törzsnél valamennyi gyógyszer esetében, igaz eltérő mértékkel.
Kovács, Dóra
core
In vitro activity of Rezafungin (CD101) against Candida species
, 2021 The in vitro antifungal activity of rezafungin, a second-generation echinocandin, was compared to other commonly-used antifungals. The inhibitory activity of antifungals against common and rare Candida species was tested using broth microdilution method.
Barabas, Kristina
core
IDCasesIntroduction: Invasive candidiasis is a common healthcare-associated infection with significant morbidity and mortality. Candida auris in particular has emerged as a problematic and challenging healthcare-associated infection, especially with regards to ...
Matthew A. Stack +5 more
doaj +1 more source
Rezafungin Versus Caspofungin for the Treatment of Candidemia and Invasive Candidiasis: Results from the Double-blind, Randomized, Phase 3 ReSTORE Trial Including the China Extension Study. [PDF]
Open Forum Infect DisBACKGROUND: Rezafungin is approved for use in adults with candidemia and/or invasive candidiasis (IC) based on data from the ReSTORE trial (NCT03667690), which demonstrated noninferior efficacy to caspofungin.
Thompson GR +12 more
europepmc +2 more sources
Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus [PDF]
Antimicrobial Agents and Chemotherapy, 2019 We evaluated extended-interval dosing of the investigational echinocandin rezafungin (1, 4, and 16 mg/kg on days 1, 4, and 7 postinoculation) for the treatment of disseminated invasive aspergillosis caused by azole-resistant Aspergillus fumigatus .
Nathan P. Wiederhold +6 more
openaire +2 more sources
Open Forum Infectious Diseases, 2023 Abstract Background Fluconazole (FLC) resistance (R) is common in C. glabrata (CGLA). Echinocandins (ECHs) are often used as first-line therapy. R to ECHs has been associated with FKS1 and FKS2 gene alterations.
Carvalhaes, Cecilia G +4 more
openaire +1 more source
Journal of Fungi, 2022 Several new antifungals are currently in late-stage development, including those with novel pharmacodynamics/mechanisms of action that represent new antifungal classes (manogepix, olorofim, ATI-2307, GR-2397). Others include new agents within established
Nathan P. Wiederhold
doaj +1 more source